{"tid":2443918,"cid":5,"subCid":0,"title":"以色列衛生部：輝瑞/BioNTech疫苗接種第二劑後有效率達97%","createTime":"2021-03-12T10:43:24.000Z","updateTime":"2021-03-12T15:56:41.000Z","uid":391580,"like":10,"dislike":0,"uniUserReply":7,"replies":[{"pid":"6020ba18c1fbb71503efda597141dd86b0ce9cc7","tid":2443918,"uid":391580,"like":0,"dislike":0,"score":0,"citedBy":2,"replyTime":"2021-03-12T10:43:24.000Z","msg":"以色列衛生部（MoH）宣布，真實世界證據顯示，在完全接種輝瑞（NYSE<img src=\"/assets/faces/normal/tongue.gif\" class=\"hkgmoji\" />FE）/BioNTech（NASDAQ:BNTX）的新冠疫苗（BNT162b2）的群體中，新冠發病率明顯降低。<br />\n<br />\n最新分析證明，第二劑疫苗接種兩週後，疫苗的保護作用更為強烈，對有症狀的新冠病例、住院和死亡的有效性至少為97%，對無症狀感染的預防效力達94%。<br />\n<br />\n今年1月，輝瑞和以色列衛生部合作監測輝瑞/BioNTech疫苗的現實影響。這項合作的詳細結果也將提交同行評議的期刊。<br />\n<br />\n以色列衛生部的分析是在超過80%的檢測樣本均為B.1.1.7（最初在英國發現）的新冠突變病毒株中進行。由於B.1.351（最初在南非發現）的新冠毒株在以色列引起的感染數量有限，該分析無法評估針對B.1.351的疫苗有效性。<br />\n<br />\n疫苗有效性評估與BNT162b2對新冠病毒的95%疫苗療效<br />\n<br />\n（資料來源：seeking alpha）"},{"pid":"f388d1737e06b0e5472417662e8037fa706539c6","tid":2443918,"uid":188282,"like":2,"dislike":0,"score":2,"citedBy":0,"replyTime":"2021-03-12T10:48:56.000Z","msg":"信以色列"},{"pid":"0cef20ad8c560a60d39f297980aa9ab0662f14ac","tid":2443918,"uid":59570,"like":2,"dislike":0,"score":2,"citedBy":2,"replyTime":"2021-03-12T10:55:33.000Z","msg":"傻仔先打科興"},{"pid":"52dc794b96807b0e67338778833b9a469d621c60","tid":2443918,"uid":297997,"like":0,"dislike":0,"score":0,"quote":{"pid":"0cef20ad8c560a60d39f297980aa9ab0662f14ac","tid":2443918,"uid":59570,"like":2,"dislike":0,"score":2,"citedBy":2,"replyTime":"2021-03-12T10:55:33.000Z","msg":"傻仔先打科興"},"citedBy":0,"replyTime":"2021-03-12T10:58:08.000Z","msg":"奧支會叫運動員打<img src=\"/assets/faces/dog/smile.gif\" class=\"hkgmoji\" />"},{"pid":"aafd7d852cb87c924944baefdc5b15ecaeb9cf6c","tid":2443918,"uid":37396,"like":1,"dislike":0,"score":1,"citedBy":0,"replyTime":"2021-03-12T11:01:40.000Z","msg":"所以香港啲專家咪爭住打<img src=\"/assets/faces/normal/hehe.gif\" class=\"hkgmoji\" /><img src=\"/assets/faces/normal/hehe.gif\" class=\"hkgmoji\" /><img src=\"/assets/faces/normal/hehe.gif\" class=\"hkgmoji\" />"},{"pid":"db9b89e8fe1f6e2b05d5d586170daa161d83b996","tid":2443918,"uid":226851,"like":0,"dislike":4,"score":-4,"quote":{"pid":"6020ba18c1fbb71503efda597141dd86b0ce9cc7","tid":2443918,"uid":391580,"like":0,"dislike":0,"score":0,"citedBy":2,"replyTime":"2021-03-12T10:43:24.000Z","msg":"以色列衛生部（MoH）宣布，真實世界證據顯示，在完全接種輝瑞（NYSE<img src=\"/assets/faces/normal/tongue.gif\" class=\"hkgmoji\" />FE）/BioNTech（NASDAQ:BNTX）的新冠疫苗（BNT162b2）的群體中，新冠發病率明顯降低。<br />\n<br />\n最新分析證明，第二劑疫苗接種兩週後，疫苗的保護作用更為強烈，對有症狀的新冠病例、住院和死亡的有效性至少為97%，對無症狀感染的預防效力達94%。<br />\n<br />\n今年1月，輝瑞和以色列衛生部合作監測輝瑞/BioNTech疫苗的現實影響。這項合作的詳細結果也將提交同行評議的期刊。<br />\n<br />\n以色列衛生部的分析是在超過80%的檢測樣本均為B.1.1.7（最初在英國發現）的新冠突變病毒株中進行。由於B.1.351（最初在南非發現）的新冠毒株在以色列引起的感染數量有限，該分析無法評估針對B.1.351的疫苗有效性。<br />\n<br />\n疫苗有效性評估與BNT162b2對新冠病毒的95%疫苗療效<br />\n<br />\n（資料來源：seeking alpha）"},"citedBy":0,"replyTime":"2021-03-12T15:55:16.000Z","msg":"<a href=\"https://www.webmd.com/vaccines/covid-19-vaccine/news/20210309/s-african-variant-challenges-pfizer-moderna-vaccines\" data-sr-url=\"https://r.lihkg.com/link?u=https%3A%2F%2Fwww.webmd.com%2Fvaccines%2Fcovid-19-vaccine%2Fnews%2F20210309%2Fs-african-variant-challenges-pfizer-moderna-vaccines&d=RGPktlJYpqjIeXpZRAkgw9UqyFx8t7fe88%2BQEXu6%2F%2FM%3D&h=56155271\" data-auto-link target=\"_blank\">https://www.webmd.com/vaccines/covid-19-vaccine/news/20210309/s-african-variant-challenges-pfizer-moderna-vaccines</a><br />\n<br />\n輝瑞疫苗對南非變種病毒效力大減10 倍。。<br />\n以色列人準備要全民大多兩針都得啦。。<img src=\"/assets/faces/normal/dead.gif\" class=\"hkgmoji\" /><img src=\"/assets/faces/normal/dead.gif\" class=\"hkgmoji\" /><img src=\"/assets/faces/normal/dead.gif\" class=\"hkgmoji\" />"},{"pid":"512c312de850cfd4974dbdf6264d38d1d5bb3af7","tid":2443918,"uid":226851,"like":0,"dislike":1,"score":-1,"quote":{"pid":"6020ba18c1fbb71503efda597141dd86b0ce9cc7","tid":2443918,"uid":391580,"like":0,"dislike":0,"score":0,"citedBy":2,"replyTime":"2021-03-12T10:43:24.000Z","msg":"以色列衛生部（MoH）宣布，真實世界證據顯示，在完全接種輝瑞（NYSE<img src=\"/assets/faces/normal/tongue.gif\" class=\"hkgmoji\" />FE）/BioNTech（NASDAQ:BNTX）的新冠疫苗（BNT162b2）的群體中，新冠發病率明顯降低。<br />\n<br />\n最新分析證明，第二劑疫苗接種兩週後，疫苗的保護作用更為強烈，對有症狀的新冠病例、住院和死亡的有效性至少為97%，對無症狀感染的預防效力達94%。<br />\n<br />\n今年1月，輝瑞和以色列衛生部合作監測輝瑞/BioNTech疫苗的現實影響。這項合作的詳細結果也將提交同行評議的期刊。<br />\n<br />\n以色列衛生部的分析是在超過80%的檢測樣本均為B.1.1.7（最初在英國發現）的新冠突變病毒株中進行。由於B.1.351（最初在南非發現）的新冠毒株在以色列引起的感染數量有限，該分析無法評估針對B.1.351的疫苗有效性。<br />\n<br />\n疫苗有效性評估與BNT162b2對新冠病毒的95%疫苗療效<br />\n<br />\n（資料來源：seeking alpha）"},"citedBy":0,"replyTime":"2021-03-12T15:56:03.000Z","msg":"The key finding: The percentage of positive antibodies that neutralized the South African variant was 12.4 fold lower for the Moderna vaccine than against the original coronavirus and 10.3 fold lower for the Pfizer vaccine, the study says."},{"pid":"8d03a4523ed1eaad66ab201eead6135cbd1e98d0","tid":2443918,"uid":7369,"like":1,"dislike":0,"score":1,"quote":{"pid":"0cef20ad8c560a60d39f297980aa9ab0662f14ac","tid":2443918,"uid":59570,"like":2,"dislike":0,"score":2,"citedBy":2,"replyTime":"2021-03-12T10:55:33.000Z","msg":"傻仔先打科興"},"citedBy":0,"replyTime":"2021-03-12T15:56:41.000Z","msg":"咪係，死鳩咗都一定冇錢賠"}]}